Is it time to revisit standard post-remission therapy?

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 4, 2012, Pages 437-441

  Stone, Richard M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia (AML); maintenance; post remission; risk adapted; standard therapy; transplant

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; HISTAMINE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; NUCLEOPHOSMIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; REMISSION INDUCTION;

EID: 84870660109     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.10.006     Document Type: Review

References (22)

1. R.J. Mayer, R.B. Davis, and C.A. Schiffer Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 331 1994 896 903
2. C.D. Bloomfield, D. Lawrence, and J.C. Byrd Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 1998 4173 4179
3. A. Neubauer, K. Maharry, and K. Mrozek Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study J Clin Oncol 26 2008 4603 4609
4. J.P. Patel, M. Gonen, and M.E. Figueroa Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N Engl J Med 366 2012 1079 1089
5. J.O. Moore, S.L. George, and R.K. Dodge Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Blood 105 2005 3420 3427
6. J.E. Kolitz, S.L. George, and G. Marcucci P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 Blood 116 2010 1413 1421
7. R.F. Schlenk, K. Dohner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
8. G. Marcucci, K. Mrozek, and M.D. Radmacher The prognostic and functional role of microRNAs in acute myeloid leukemia Blood 117 2011 1121 1129
9. G. Marcucci, M.D. Radmacher, and K. Maharry MicroRNA expression in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1919 1928
10. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
11. D. Cilloni, A. Renneville, and F. Hermitte Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study J Clin Oncol 27 2009 5195 5201
12. T. Buchner, W.E. Berdel, and C. Schoch Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia J Clin Oncol 24 2006 2480 2489
13. M. Buyse, P. Squifflet, and B.J. Lange Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia Blood 117 2011 7007 7013
14. M.R. Baer, S.L. George, and M.A. Caligiuri Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 J Clin Oncol 26 2008 4934 4939
15. M. Brune, S. Castaigne, and J. Catalano Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood 108 2006 88 96
16. S. Castaigne, C. Pautas, and C. Terre Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemother (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA) Blood (ASH Annu Meet Abstracts) 118 2011 abstr 6
17. E.H. Estey, F.J. Giles, and H. Kantarjian Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia Blood 94 1999 2230 2235
18. D.W. Milligan, K. Wheatley, and T. Littlewood Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial Blood 107 2006 4614 4622
19. R.F. Schlenk, K. Dohner, and M. Kneba Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B Haematologica 94 2009 54 60
20. R.F. Schlenk, K. Dohner, and J. Krauter All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia - results of the AMLSG07-04 randomized trial Blood (ASH Annu Meet Abstracts) 118 2011 abstr 80
21. J. Koreth, R. Schlenk, and K.J. Kopecky Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials JAMA 301 2009 2349 2361
22. E. Estey, M. de Lima, and R. Tibes Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood 109 2007 1395 1400